NAVB | tickerfilter.com

Fundamental analysis

22%

Profitability 0%

Dept financing 50%

Liquidity 13%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

-97.50%

2 Year

-99.62%

Key data

Stock price

$0.08

P/E Ratio

-0.01

DAY RANGE

N/A - N/A

EPS

-$0.67

52 WEEK RANGE

$0.00 - $0.13

52 WEEK CHANGE

-$97.50

MARKET CAP

100.084 K

YIELD

N/A

SHARES OUTSTANDING

100.084 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

N/A

Company detail

CEO: Michael S. Rosol
Region: US
Website: navidea.com
Employees: 10
IPO year: 1992

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Navidea Biopharmaceuticals, Inc. focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability.

NAVB - NAVIDEA BIOPHARMACEUTICALS, INC.